CVACCureVac N.V.

Nasdaq curevac.com


$ 3.89 $ 0.12 (3.18 %)    

Friday, 31-May-2024 15:59:49 EDT
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 3.89
$ 3.97
$ 0.00 x 0
$ 0.00 x 0
$ 3.76 - $ 4.03
$ 2.22 - $ 12.36
1,105,122
na
871.32M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 covid-19-patent-dispute-sorted-acuitas-therapeutics-and-curevac-reach-settlement-in-patent-battle

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfi...

 leerink-partners-downgrades-curevac-to-market-perform-lowers-price-target-to-4

Leerink Partners analyst Mani Foroohar downgrades CureVac (NASDAQ:CVAC) from Outperform to Market Perform and lowers the pri...

Core News & Articles

https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collabora...

 guggenheim-reiterates-neutral-on-curevac

Guggenheim analyst Evan Wang reiterates CureVac (NASDAQ:CVAC) with a Neutral.

 curevac-gsk-partner-release-data-on-influenza-vaccine-study

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen c...

Core News & Articles

CureVac N.V. (NASDAQ:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION